CFM
SGMO

Catalyst Funds Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Catalyst Funds Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-54,385
Closed -$35.7K – 675
2025
Q1 		$35.7K Buy
+54,385
New +$57.6K 0.01% 423
2024
Q3 		– Sell
-38,200
Closed -$13.7K – 1573
2024
Q2 		$13.7K Buy
+38,200
New +$20.6K ﹤0.01% 815

Other funds holding SGMO

YAG
Yorkville Advisors Global Mountainside, New Jersey $155M AUM 58.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Catalyst Funds Management's SGMO Position: Q2 2025 in Review

Catalyst Funds Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2025, closing a stake of 54,385 shares — an estimated $35.7K sold.

Catalyst Funds Management first reported a position in SGMO in Q2 2024 and held it in 2 quarters. The position peaked at $35.7K in Q1 2025. 114 funds tracked by Wall St. Rank hold SGMO as of Q2 2025.

  • Catalyst Funds Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • Catalyst Funds Management sold 54,385 SANGAMO THERAPEUTICS INC shares in Q2 2025, an estimated $35.7K.
  • Catalyst Funds Management first reported a position in SANGAMO THERAPEUTICS INC in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's SANGAMO THERAPEUTICS INC position peaked at $35.7K in Q1 2025.
  • 114 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2025.

Based on Catalyst Funds Management's 13F filing for Q2 2025, filed 12 Aug 2025.